Inventors: George Prendergast and Kai Ge

Tech ID: PG-98002

Description: Bin1/Amphiphysin/BVS (BAR) proteins comprise a family of adaptor proteins that are implicated in many cellular processes, such as tumorigenesis, cell survival, differentiation, and synaptic activity. While BAR proteins share the common BAR domain, they have different physiological functions.

Wistar scientists have identified a new member of the BAR protein family, BIN-2. BIN-2 appears to be expressed primarily in hematopoietic cells and to be altered in hepatocellular tumors. BIN-2 forms stable complexes with other BAR proteins, such as Bin1.

Key Words: Cancer, target, gene therapy, hepatocarcinoma

Applications and Advantages: BIN-2 may be useful for the diagnosis and/or treatment of cancers, particularly hepatocarcinomas.

Intellectual Property Status: US and international patent applications have been filed (see PCT/US00/23723).

Licensing Opportunity: This technology is available for exclusive or non-exclusive licensing.

Contact:

Meryle J. Melnicoff
Director, Business Development
The Wistar Institute
3601 Spruce Street
Philadelphia, PA 19104
Phone: (215) 898-0049
Fax: (215) 573-2456
melnicoff@wistar.org

Last Updated: Jul-01